FDA Clearance Tracker · P150045
ZEUS ELISA PARVOVIRUS B19 IGG TEST SYSTEM
Last checked: Nov 19, 2026Latest source record: Sep 19, 2017 (this decision)Source: openFDAMethods & limitations
Decided
Sep 19, 2017
Approved
Time to decision
665 days
Received Nov 24, 2015. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P150045
- Device name
- ZEUS ELISA PARVOVIRUS B19 IGG TEST SYSTEM
- Applicant
- Zeus Scientific, Inc.
- Applicant location
- Branchburg, NJ
- Received
- Nov 24, 2015
- Decided
- Sep 19, 2017
- Decision
- Approved
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for the ZEUS ELISA Parvovirus B19 IgG Test System is intended for the qualitative detection of IgG class antibodies to human parvovirus B19 in human serum including women of childbearing age where there is a suspicion of exposure to human parvovirus B19. The test is also for all symptomatic patients as an aid in the diagnosis of fifth disease (erythema infectiosum). This test is for in vitro diagnostic use only.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code MYL. The earliest in FDA's data is P970054, decided Aug 6, 1999.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Zeus Scientific, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K201956 · Decided Apr 29, 2022 · 654 days after receipt
Device type: Antinuclear Antibody, Indirect Immunofluorescent, Antigen, Control (DHN) · Laboratory Medicine & Pathology
K190907 · Decided Jul 29, 2019 · 112 days after receipt
Device type: Reagent, Borrelia Serological Reagent (LSR) · Laboratory Medicine & Pathology
K191240 · Decided Jul 29, 2019 · 82 days after receipt
Device type: Reagent, Borrelia Serological Reagent (LSR) · Laboratory Medicine & Pathology
2 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.